Zydus’ Nesher Pharmaceuticals receives USFDA nod for Dextroamphetamine Sulfate capsules

29 Jun 2017 Evaluate

Zydus Cadila’s Nesher Pharmaceuticals has received US Food and Drug Administration (USFDA) approval for Dextroamphetamine Sulfate Extended-Release Capsules. Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received final approval from the USFDA to market Dextroamphetamine Sulfate Extended-Release Capsules, 5 mg.

The drug will be produced at the Nesher Pharmaceuticals’ manufacturing facility located at St. Louis, MO, USA. Dextroamphetamine is a central nervous system stimulant used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and in the treatment of narcolepsy (a special type of sleep disorder).

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.



Zydus Lifesciences Share Price

881.95 -2.90 (-0.33%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×